Susan G. Komen

A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.

[Susan G. Komen @SusanGKomen]

@NTungMD
@marijasullivan, Mariana Chavez MacGregor, MD
@anaelisalohman1

#ASCO26 @ASCO

[Susan G. Komen @SusanGKomen]

Thrilled to see many Komen-supported grantees & posters at #ASCO26. Each reflects scientific progress and the dedication of researchers improving outcomes for people impacted by breast cancer. Proud to support science, moving us closer to a world without breast cancer. @ASCO

[Susan G. Komen @SusanGKomen]

Marni Blair McClure, MD, PhD, @cncurtis, @AllisonKurian, @caswell_jin
Laura Burns Amin, MD, Mariana Chavez MacGregor, MD, @shgiordano
Harikrishna Nakshatri, PhD

#ASCO26 @ASCO

[Susan G. Komen @SusanGKomen]

🧬 Sara Hurvitz, MD presents VIKTORIA-1 at #ASCO26: In HR+/HER2- PIK3CA-mutant breast cancer after CDK4/6i, gedatolisib + fulvestrant (with or without palbociclib) doubled progression-free survival vs standard of care (11.1 vs 5.6 months). 🎯 @ASCO

[Susan G. Komen @SusanGKomen]

🧬 Francois Bidard, MD, Ph.D. presents SERENA-6 at #ASCO26: Switching to camizestrant + CDK4/6i when ESR1 mutations emerge during first-line therapy improved outcomes through 2 lines of treatment in HR+/HER2- advanced breast cancer @ASCO

[Susan G. Komen @SusanGKomen]

GLP-1 use is rising but what about #breastcancer risk? Long term safety matters.

At #ASCO26, Elizabeth Susan McDonald, MD, PhD reported GLP-1 treatment was associated with lower BC incidence in women, but clinical trials are needed to confirm a true risk reduction effect. @ASCO

[Susan G. Komen @SusanGKomen]

PANKU-Breast02 phase 3 trial: iza-bren vs chemo in pre-treated metastatic TNBC.
Jiong Wu, MD, PhD reported that patients had improved overall survival & stayed progression-free longer w/ manageable side effects, suggesting iza-bren could become a new standard option @ASCO #ASCO26

[Susan G. Komen @SusanGKomen]

Can ADCs improve outcomes in pts who can't get immunotherapy?

At #ASCO26, David Cescon, MD, PhD shared new TROPION-Breast02 data: Dato-DXd helped pts go longer w/o progression & delayed need for further tx vs chemo, supporting it as a potential new 1L standard in mTNBC. @ASCO

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

@DanaFarber's Dr. Sara Tolaney presenting updated results from the ASCENT-03 trial, looking at sacituzumab govitecan vs chemo in 1L metastatic @TNBC, at #asco26. #BreastCancer #bcsm

[Susan G. Komen @SusanGKomen]

🧬@KalinskyKevin presents ASCENT-04 at #ASCO26: Starting on sacituzumab govitecan + pembro upfront led to better outcomes through 2 lines of treatment in PD-L1+ metastatic TNBC - even vs patients who eventually received SG later. @ASCO

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Dr. Sara Tolaney (@stolaney1) sharing updated results from the ASCENT-03 study at @asco26. The results further support first line sacituzumab govitecan use for patients with metastatic #TNBC who are not candidates for PD-(L)1 inhibitors.

[Susan G. Komen @SusanGKomen]

ASCENT-03 tests sacituzumab govitecan (SG) vs chemo in 1L metastatic TNBC

@stolaney1 presented new data showing improved PFS after next line of treatment & subsequent therapies, supporting SG as a potential new standard of care for those not eligible for PD-L1 therapy. @ASCO

[Susan G. Komen @SusanGKomen]

At #ASCO26, Komen grantee @shgiordano, the recipient of the Gianni Bonadonna Breast Cancer Award, shared insights on opportunities, challenges and lessons learned in breast cancer outcomes research 🏆

@ASCO

[Susan G. Komen @SusanGKomen]

New insights from Komen-funded phase 3 BWEL trial evaluating the impact of a weight loss intervention (WLI) on QOL and symptoms in women with #breastcancer 📊 presented by Komen Scholar Jennifer Ligibel, MD at #ASCO26 showed that the WLI had improved physical function & QOL.

[Susan G. Komen @SusanGKomen]

💡 Adolescent & young adults face unique survivorship challenges. The Komen-supported YES study evaluates a mobile health intervention for young patients with #breastcancer.📱 @ShoshRosenberg presents data at #ASCO26 showing the intervention eases some of these unique concerns.

[Laura Esfeller @LauraEsfeller]

The incredible @ARosen380 on a @SusanGKomen panel on #AYACancers at #ASCO26 talking about the lack of survivorship planning for long-term survivors. “I had to create my own survivorship plan.” As patients like Allison and I live longer, we’re putting the wheels on the bus while the bus is on the road. This is even more challenging for patients like us who aren’t seen in AYA settings. It’s going to take us all - patients, PCPs, oncs, surgeons, etc - to solve this.

[Susan G. Komen @SusanGKomen]

Phase 3 KEYNOTE-522 final results 👀💥 @JavierCortesMD presents data from the trial evaluating pembrolizumab + chemo before surgery, followed by adjuvant pembrolizumab vs placebo. #ASCO26 @ASCO

[Susan G. Komen @SusanGKomen]

Recurrence remains a challenge in HR+/HER2- early #breastcancer. Phase 3 lidERA trial previously showed improvement with giredestrant (oral SERD) vs standard hormone therapy 📈

Peter Schmid, MD, PhD presents results by menopausal status at #ASCO26 @ASCO

[Susan G. Komen @SusanGKomen]

New biomarker insights from NATALEE trial presented by Stephen Chia, MD 📊

Baseline gene expression shows prognostic & predictive impact in HR+/HER2- early #breastcancer treated with adjuvant ribociclib + aromatase inhibitor #ASCO26 @ASCO

[Susan G. Komen @SusanGKomen]

Can some people safely avoid chemo in higher-risk early breast cancer? 🤔

OPTIMA phase 3 tests a genomic-guided strategy vs standard of care in HR+/HER2- #breastcancer. Robert Stein, PhD presents first results at #ASCO26. @ASCO